Trial Profile
A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Meiji Seika Pharma
- 15 Mar 2022 Results of post-hoc analysis assessing response according to background factors, published in the Journal of the Neurological Sciences.
- 15 Oct 2021 Results of post-hoc analysis assessing efficacy and safety of safinamide as an add-on therapy to a stable dose of levodopa in patients with PD who were experiencing wearing-off, published in the Journal of the Neurological Sciences.
- 22 Sep 2021 Results of post-hoc analysis assessing efficacy of safinamide for mood and pain, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.